Pfizer AstraZeneca Europe next coronavirus vaccines: The week dawned with the news that the vaccine from Pfizer and BioNTech prevented contagion in 90% of cases, an effectiveness greater than 50% that Dr. Anthony Fauci, leading expert in infectious diseases in the United States, had anticipated that it would be acceptable.

The Minister of Health, Salvador Illa, was quick to communicate that the European Union was finalizing an agreement with Pfizer with which Spain would correspond about 20 million doses of the promising vaccine, in case it finally gets approved.

This has been thanks to the strategy that the European Commission presented on August 14 to expedite the development, manufacture and deployment of effective and safe vaccines against COVID-19 through the agreement of advance purchase of vaccines against COVID-19.

"In exchange for the right to purchase a certain number of doses of vaccines in a given period, the commission would finance part of the initial costs of vaccine producers through an advance market commitment. The funding provided would be considered a payment on behalf of the vaccines that the member states actually buy," explains the agency itself.

"As the high cost and high failure rate make investing in a COVID-19 vaccine a high-risk decision for vaccine developers, these commitments will allow for investments that would otherwise probably not occur," he adds.

The agreements being acquired by the European Commission offer member countries the possibility of acquiring the vaccine and, in some cases, also the possibility of making donations to middle and low income countries or redirecting it to European countries.

In addition to the Pfizer vaccine, Spain has confirmed that it adheres to the centralized purchase of the doses agreed with AstraZeneca and for which it corresponds 30 million doses, as well as the agreements signed with Johnson & Johnson and Sanofi.

Pfizer AstraZeneca Europe next coronavirus vaccines

Our country is one of seven that are part of the negotiating team that acts as an interlocutor with the companies that are developing a vaccine and that will increase the portfolio of vaccines as it closes more agreements with other companies.

These are all the companies with which the European Commission is talking to ensure a vaccine against coronavirus and to which Spain will have access.

The first purchase: 300 million doses of the vaccine from the UK

"On August 14, the Commission reached a first agreement with the pharmaceutical company AstraZeneca to acquire a possible vaccine against coronavirus and to donate or transfer vaccines to other European countries and to other middle or low income countries. As agreed, when the vaccine has proven safe and effective against coronavirus, the Commission will acquire 300 million doses on behalf of the member states, with the possibility of an additional acquisition of 100 million doses," the European Commission announced.

  • Company: Astra Zeneca with Oxford University.
  • Type of vaccine: based on an adenovirus.
  • When approval is expected: the vaccine from AstraZeneca and the University of Oxford is already being tested on more than 10,000 volunteers as part of Phase 3 trials and they hope that by Autumn their vaccine will be ready for possible emergency use
  • Results known so far: the first data reveal that it induces immunity without serious side effects.
  • Price of doses: the economic details of the EC agreement with Astra Zeneca have not transcended. The company has assured that it will sell at cost price and that the manufacture of each dose costs only a couple of dollars. According to statements collected by Reuters, the Italian health minister would have encrypted at 2,5 euros the cost of each dose.

The EU has already secured the purchase of 300 million doses of Pfizer's vaccine with BioNTech

"The European Commission has today approved a fourth contract with the pharmaceutical companies BioNTech and Pfizer, which provides for the initial purchase of 200 million doses on behalf of all member states of the European Union, plus an option to request up to another 100 million doses, which will be supplied once a vaccine has been proven to be safe and effective against COVID-19," the body recently said.

  • Company: Pfizer and BioNTech.
  • Vaccine type: mRNA
  • When approval is expected: the companies have assured that they will seek emergency authorization this year.
  • Results known so far: they recently announced that the vaccine prevented contagion in 90% of cases, but the findings have yet to be published in a peer-reviewed scientific journal.
  • Price of doses: the financial data of the agreement with the EU are unknown, but an official involved assured that the cost was less than the 19.50 dollars (16.50) that the United States will pay for the doses. The price difference responds to the largest public support the vaccine has received in Europe.

The EC has also closed an agreement with the American pharmaceutical company Johnson & Johnson

The European Commission had been negotiating with Johnson & Johnson to acquire a possible coronavirus vaccine since July. Finally, in October he announced that they had closed an agreement: "once the vaccine has been proven to be safe and effective against COVID-19, the contract allows member states to buy vaccines for 200 million people. They will also have the possibility to buy vaccines for another 200 million people."

The planned contract would provide all member states with the possibility to purchase the vaccine, as well as to donate or transfer vaccines to low-and middle-income countries.

  • Company: Johnson & Johnson.
  • Type of vaccine: based on an adenovirus.
  • When approval is expected: the manufacturer is immersed in Phase 3 trials on 60,000 people, who had to be temporarily paralyzed by detecting unexpected adverse effects. The company has assured that there is a chance that you will know if the vaccine is effective before the end of the year.
  • Results known so far: the company has revealed results in a small group of volunteers and assures that they observed high doses of neutralizing antibodies in all of them.
  • Price of doses: the company has not yet determined the price of its injection, although senior executives suggest that it will be offered at cost price for the duration of the pandemic.

In September, the Commission closed an agreement that "will allow all EU member states to purchase up to 300 million doses of the Sanofi-GSK vaccine. In addition, Member States may donate the reserved doses to low-and middle-income countries."

  • Company: Sanofi and Glaxo Smith Kline.
  • Vaccine type: recombinant DNA with an adjuvant.
  • When approval is expected: "Sanofi-GSK is expected to apply for marketing authorization for its experimental vaccine from the European Medicines Agency (EMA) in June 2021, once the third phase of clinical trials yields a promising immune response," as detailed by the EC.
  • Results known so far: Sanofi and GSK started a Phase 1/2 study on September 3 with a total of 440 subjects enrolled, and anticipate having the first results in early December 2020.
  • Price of doses: Olivier Bogillot, director of Sanofi France, stated that the vaccine could have a cost of less than 10 euros, according to Reuters.

The German company CureVac, one of the companies that has ruled out selling at cost price, commits 225 million doses to the EU

"On August 20, the European Commission held exploratory talks with the German pharmaceutical company CureVac, with a view to the acquisition of a possible vaccine against coronavirus. The company is a pioneer in perfecting a completely new class of vaccines, whose platform it has developed over the last decade. The contractual framework would provide for the initial procurement of 225 million doses on behalf of all EU member states, the delivery of which would occur when the safety and efficacy of the vaccine has been demonstrated," the statement details.

  • Company: CureVac.
  • Type of vaccine: messenger RNA.
  • When approval is expected: the German company does not rule out a quick approval process for its possible COVID-19 vaccine, as its own CEO has said. However, for now it expects to put the vaccine on the market mid-2021.
  • Results known so far: in early November the company assured that the results of Phase 1 of its clinical trials revealed that the candidate was well tolerated in all doses tested and induced strong binding and neutralizing antibody responses in addition to the first indication of T-cell activation.
  • Price of doses: CureVac has been one of the companies that has ruled out selling its vaccine at cost price. Instead, he assured that he would seek an "ethical" profit margin. The CFO has declined to specify a figure, but warned that the final price "would depend on dose and not on costs," according to the Financial Times.

EU negotiates with Moderna a possible purchase of 80 million doses

The European Commission is in talks with Moderna to acquire 80 million doses of its vaccine against coronavirus, as reported by the biotech itself.

"The possible purchase agreement with the European Commission of 80 million doses provides for an option for Member States to purchase an additional 80 million doses for a total of up to 160 million doses," detailed the company's information.

  • Company: Moderna.
  • Type of vaccine: messenger RNA.
  • When approval is expected: it has recently announced that it will soon be ready to announce the results of the last phase of clinical trials.
  • Results known so far: the company has made public the results of the first phase of the human trial, which reveal that it is safe and generates an immune response through antibodies.
  • Price of doses: the company has not yet put an official figure to its vaccine, but it has advanced that it values to market it with a price while the pandemic lasts and raise it afterwards. Biotech could be considering selling the dose for between 25 and 30 dollars (between 21 and 25 euros), as sources familiar with the matter have assured the Financial Times. Considering that two doses would be needed, that puts the final price of the modern vaccine between 50 and 60 dollars (between 42.6 and 51 euros).

Pfizer AstraZeneca Europe next coronavirus vaccines


Your new home office - Take working from home to the next level with our range of fully insulated garden office products and enjoy 10 years guarantee: GARDEN OFFICES

You may also find interesting: